Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

news press-release press-release-detail pfizer-and-biontech-sign-new-global-collaboration-agreement

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis

The Pharma Data

APRIL 26, 2021

Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with continued strong growth from Entresto (+34% cc), Zolgensma (+81% cc), and Cosentyx (+11% cc). Kesimpta sales reached USD 50 million. Oncology BU grew +1% (cc, +4% USD) driven by Kymriah (+55% cc), Promacta/Revolade (+13% cc), Kisqali (+19% cc) and Jakavi (+8% cc).

Sales

Sales Medicine Production Manufacturing

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

The United States isn’t among the 78 high-income countries who have signed onto a global vaccine allocation plan that guarantees members access to a large portfolio of vaccines as is currently promoted by WHO. “Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Moderna’s COVID-19 Vaccine.

Vaccination

Vaccination Vaccine Antibody Life Science

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis

COVID-19 Pandemic Coverage

Stay Connected